Drug Fees, Pharmacy Dispensing Fees, and Pharmacy Supply Fees

EFFECTIVE 10/01/2024 THROUGH 12/31/2024

The absence or presence of a HCPCS code and the fee in this list does not indicate Medicare coverage of the drug.



HCPCS Code / NDC Number	Description	Dosage	Fee
G0333	PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY		\$57.000
J0133	INJECTION, ACYCLOVIR	5 MG	\$0.026
J0285	INJECTION, AMPHOTERICIN B	50 MG	\$48.957
J0287	INJECTION, AMPHOTERICIN B LIPID COMPLEX	10 MG	\$11.130
J0288	INJECTION, AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX	10 MG	INVOICE*
J0289	INJECTION, AMPHOTERICIN B LIPOSOME	10 MG	\$23.325
J0739	INJECTION, CABOTEGRAVIR, 1MG, FDA APPROVED PRESCRIPTION, ONLY FOR USE AS HIV PRE-EXPOSURE PROPHYLAXIS (NOT FOR USE AS TREATMENT FOR HIV)		\$6.741
J0750	EMTRICITABINE 200MG AND TENOFOVIR DISOPROXIL FUMARATE 300MG, ORAL,FDA APPROVED PRESCRIPTION, ONLY FOR USE AS HIV PRE-EXPOSURE PROPHYLAXIS (NOT FOR USE AS TREATMENT OF HIV)		\$1.062
J0751	EMTRICITABINE 200MG AND TENOFOVIR ALAFENAMIDE 25MG, ORAL, FDA APPROVED PRESCRIPTION, ONLY FOR USE AS HIV PRE-EXPOSURE PROPHYLAXIS (NOT FOR USE AS TREATMENT OF HIV)		\$75.612
J0799	FDA APPROVED PRESCRIPTION DRUG, ONLY FOR USE AS HIV PRE-EXPOSURE PROPHYLAXIS 9NOT FOR USE AS TREATMENT OF HIV), NOT OTHERWISE CLASSIFIED		INVOICE*
J0895	INJECTION, DEFEROXAMINE MESYLATE	500 MG	\$6.778
J1171	INJECTION, HYDROMORPHONE	0.1 MG	\$0.085
J1250	INJECTION, DOBUTAMINE HYDROCHLORIDE	250 MG	\$7.928
J1265	INJECTION, DOPAMINE HCL	40 MG	\$0.721
J1325	INJECTION, EPOPROSTENOL	0.5 MG	\$15.860
J1455	INJECTION, FOSCARNET SODIUM	1000 MG	\$83.506
J1459	INJECTION, IMMUNE GLOBULIN (PRIVIGEN), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID)	500 MG	\$48.579
J1551	INJECTION, IMMUNE GLOBULIN (CUTAQUIG)	100 MG	\$14.498
J1554	INJECTION, IMMUNE GLOBULIN (ASCENIV)	500 MG	\$491.404
J1555	INJECTION, IMMUNE GLOBULIN (CUVITRU)	100 MG	\$16.820
J1556	INJECTION, IMMUNE GLOBULIN (BIVIGAM)	500 MG	\$75.171
J1557	INJECTION, IMMUNE GLOBULIN, (GAMMAPLEX), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID)	500 MG	\$57.925
J1558	INJECTION, IMMUNE GLOBULIN (XEMBIFY)	100 MG	\$14.295
J1559	INJECTION, IMMUNE GLOBULIN (HIZENTRA)	100 MG	\$13.232
J1561	INJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID)	500 MG	\$48.805
J1561JB	INJECTION, IMMUNE GLOBULIN, (GAMUNEX-C/GAMMAKED), NON-LYOPHILIZED (E.G. LIQUID) [JB modifier indicates drug being administered subcutaneously]	500 MG	Same as J1561**
J1562	INJECTION, IMMUNE GLOBULIN (VIVAGLOBIN)	100 MG	INVOICE*
J1566	INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED (E.G. POWDER), NOT OTHERWISE SPECIFIED	500 MG	\$82.192
J1568	INJECTION, IMMUNE GLOBULIN, (OCTAGAM), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID)	500 MG	\$48.995

^{*} Invoice indicates an invoice for drug should be submitted when filing claim





^{**} Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier.

HCPCS Code /				
NDC Number	Description	Dosage	Fee	
J1569	INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID)	500 MG	\$49.692	
J1569JB	INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G. LIQUID) [JB modifier indicates drug being administered subcutaneously]	500 MG	Same as J1569**	
J1570	INJECTION, GANCICLOVIR SODIUM	500 MG	\$36.406	
J1572	INJECTION, IMMUNE GLOBULIN, (FLEBOGAMMA/FLEBOGAMMA DIF), INTRAVENOUS, NON-LYOPHILIZED (E.G. LIQUID)	500 MG	\$56.116	
J1575	INJECTION, IMMUNE GLOBULIN/HYALURONIDASE, (HYQVIA)	100 MG	\$17.503	
J1576	INJECTION, IMMUNE GLOBULIN (PANZYGA), INTRAVENOUS, NON-LYOPHILIZED (E.G., LIQUID)	500 MG	\$67.461	
J1811	INSULIN (FIASP) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP)	50 UNITS	\$7.413	
J1813	INSULIN (LYUMJEV) FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP)	50 UNITS	\$15.534	
J1817	INSULIN FOR ADMINISTRATION THROUGH DME (I.E., INSULIN PUMP)	50 UNITS	\$2.462	
J2175	INJECTION, MEPERIDINE HYDROCHLORIDE	100 MG	\$6.517	
J2260	INJECTION, MILRINONE LACTATE	5 MG	\$1.413	
J2270	INJECTION, MORPHINE SULFATE	UP TO 10 MG	\$4.841	
J2274	INJECTION, MORPHINE SULFATE, PRESERVATIVE-FREE FOR EPIDURAL OR INTRATHECAL USE	10 MG	\$10.463	
J2278	INJECTION, ZICONOTIDE	1 MCG	\$9.649	
J2545	PENTAMIDINE ISETHIONATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	300 MG	\$85.531	
J2919	INJECTION, METHYLPREDNISOLONE SODIUM SUCCINATE	5 MG	\$0.304	
J3010	INJECTION, FENTANYL CITRATE	0.1 MG	\$0.903	
J3285	INJECTION, TREPROSTINIL	1 MG	\$55.815	
J7340	CARBIDOPA 5 MG/LEVODOPA 20 MG ENTERAL SUSPENSION	100 ML	\$235.060	
J7500	AZATHIOPRINE, ORAL	50 MG	\$1.616	
J7501	AZATHIOPRINE, PARENTERAL	100 MG	INVOICE*	
J7502	CYCLOSPORINE, ORAL	100 MG	\$2.387	
J7503	TACROLIMUS, EXTENDED RELEASE, (ENVARSUS XR), ORAL	0.25 MG	\$1.767	
J7504	LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, EQUINE, PARENTERAL	250 MG	\$3,968.446	
J7507	TACROLIMUS, IMMEDIATE RELEASE, ORAL	1 MG	\$0.255	
J7508	TACROLIMUS, EXTENDED RELEASE, ORAL	0.1 MG	\$0.567	
J7509	METHYLPREDNISOLONE, ORAL	4 MG	\$0.244	
J7510	PREDNISOLONE, ORAL	5 MG	\$0.386	
J7511	LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, RABBIT, PARENTERAL	25 MG	\$956.739	
J7512	PREDNISONE, IMMEDIATE RELEASE OR DELAYED RELEASE, ORAL	1 MG	\$0.005	
J7515	CYCLOSPORINE, ORAL	25 MG	\$0.847	
J7517	MYCOPHENOLATE MOFETIL, ORAL	250 MG	\$0.175	
J7518	MYCOPHENOLIC ACID, ORAL	180 MG	\$0.442	
J7519	INJECTION, MYCOPHENOLATE MOFETIL	10 MG	\$0.517	
J7520	SIROLIMUS, ORAL	1 MG	\$1.327	
J7525	TACROLIMUS, PARENTERAL	5 MG	\$254.775	
J7527	EVEROLIMUS, ORAL	0.25 MG	\$2.206	
J7605KO	ARFORMOTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	15 MCG	\$0.682	
J7606KO	FORMOTEROL FUMARATE, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	20 MCG	\$2.381	
J7608KO	ACETYLCYSTEINE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	1 GM	\$7.772	
J7611	ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM	1 MG	\$0.181	
J7612	LEVALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, CONCENTRATED FORM	0.5 MG	\$0.233	

^{*} Invoice indicates an invoice for drug should be submitted when filing claim

^{**} Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier.

HCPCS Code /			
NDC Number	Description	Dosage	Fee
J7613KO	ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE	1 MG	\$0.071
J7614KO	LEVALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE	0.5 MG	\$0.080
J7620	ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME	1 UNIT	\$0.185
J7626KO	BUDESONIDE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	UP TO 0.5 MG	\$1.229
J7631KO	CROMOLYN SODIUM, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	10 MG	\$0.437
J7639KO	DORNASE ALPHA, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	1 MG	\$53.478
J7644KO	IPRATROPIUM BROMIDE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	1 MG	\$0.363
J7669KO	METAPROTERENOL SULFATE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	10 MG	INVOICE*
J7677	REVEFENACIN INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME	1 MCG	\$0.187
J7682KO	TOBRAMYCIN, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, UNIT DOSE FORM, ADMINISTERED THROUGH DME	300 MG	\$15.952
J7686KO	TREPROSTINIL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	1.74 MG	\$760.235
J8501	APREPITANT, ORAL	5 MG	\$3.273
J8522	CAPECITABINE, ORAL	50 MG	\$0.064
J8530	CYCLOPHOSPHAMIDE; ORAL	25 MG	\$0.883
J8540	DEXAMETHASONE, ORAL	0.25 MG	\$0.041
J8610	METHOTREXATE; ORAL	2.5 MG	\$0.224
J8650	NABILONE, ORAL	1 MG	INVOICE*
J8655	NETUPITANT AND PALONOSETRON, ORAL	300 MG and 0.5 MG	\$400.242
J8670	ROLAPITANT, ORAL	1 MG	\$1.583
J9000	INJECTION, DOXORUBICIN HYDROCHLORIDE	10 MG	\$3.302
J9039	INJECTION, BLINATUMOMAB	1 MCG	\$152.178
J9040	INJECTION, BLEOMYCIN SULFATE	15 UNITS	\$24.684
J9065	INJECTION, CLADRIBINE	1 MG	\$14.245
J9100	INJECTION, CYTARABINE	100 MG	\$0.771
J9190	INJECTION, FLUOROURACIL	500 MG	\$2.394
J9200	INJECTION, FLOXURIDINE	500 MG	\$3,858.031
J9208	INJECTION, IFOSFAMIDE	1 GM	\$24.924
J9355	INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR	10 MG	\$77.940
J9360	INJECTION, VINBLASTINE SULFATE	1 MG	\$4.433
J9370	VINCRISTINE SULFATE	1 MG	\$8.213
Q0162	ONDANSETRON, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT THE TIME OF CHEMOTHERAPY TREATMENT, NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	1 MG	\$0.013
Q0163	DIPHENHYDRAMINE HYDROCHLORIDE, ORAL, FDA APPROVED PRESCRIPTION ANTI- EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	50 MG	INVOICE*
Q0164	PROCHLORPERAZINE MALEATE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	5MG	\$0.370
Q0166	GRANISETRON HYDROCHLORIDE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 24 HOUR DOSAGE REGIMEN	1 MG	\$3.816

^{*} Invoice indicates an invoice for drug should be submitted when filing claim

^{**} Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier.

HCPCS Code /			
IDC Number	Description	Dosage	Fee
Q0167	DRONABINOL, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	2.5 MG	\$2.417
Q0169	PROMETHAZINE HYDROCHLORIDE, ORAL, FDA APPROVED PRESCRIPTION ANTI- EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	12.5 MG	\$0.085
Q0173	TRIMETHOBENZAMIDE HYDROCHLORIDE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	250 MG	INVOICE*
Q0174	THIETHYLPERAZINE MALEATE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	10 MG	INVOICE*
Q0175	PERPHENAZINE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	4 MG	\$0.494
Q0177	HYDROXYZINE PAMOATE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 48 HOUR DOSAGE REGIMEN	25 MG	\$0.140
Q0180	DOLASETRON MESYLATE, ORAL, FDA APPROVED PRESCRIPTION ANTI-EMETIC, FOR USE AS A COMPLETE THERAPEUTIC SUBSTITUTE FOR AN IV ANTI-EMETIC AT TIME OF CHEMOTHERAPY TREATMENT NOT TO EXCEED A 24 HOUR DOSAGE REGIMEN	100 MG	\$101.236
Q0510	PHARMACY SUPPLY FEE FOR INITIAL IMMUNOSUPPRESSIVE DRUG(S), FIRST MONTH FOLLOWING TRANSPLANT		\$50.000
Q0511	PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR THE FIRST PRESCRIPTION IN A 30-DAY PERIOD		\$24.000
Q0512	PHARMACY SUPPLY FEE FOR ORAL ANTI-CANCER, ORAL ANTI-EMETIC OR IMMUNOSUPPRESSIVE DRUG(S); FOR A SUBSEQUENT PRESCRIPTION IN A 30-DAY PERIOD		\$16.000
Q0513	PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 30 DAYS		\$33.000
Q0514	PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); PER 90 DAYS		\$66.000
Q0516	PHARMACY SUPPLYING FEE FOR HIV PRE-EXPOSURE PROPHYLAXIS FDA APPROVED PRESCRIPTION ORAL DRUG, PER 30-DAYS		\$24.000
Q0517	PHARMACY SUPPLYING FEE FOR HIV PRE-EXPOSURE PROPHYLAXIS FDA APPROVED PRESCRIPTION ORAL DRUG, PER 60-DAYS		\$40.000
Q0518	PHARMACY SUPPLYING FEE FOR HIV PRE-EXPOSURE PROPHYLAXIS FDA APPROVED PRESCRIPTION ORAL DRUG, PER 90-DAYS		\$56.000
Q0519	PHARMACY SUPPLYING FEE FOR HIV PRE-EXPOSURE PROPHYLAXIS FDA APPROVED PRESCRIPTION INJECTABLE DRUG, PER 30-DAYS		\$24.000
Q0520	PHARMACY SUPPLYING FEE FOR HIV PRE-EXPOSURE PROPHYLAXIS FDA APPROVED PRESCRIPTION INJECTABLE DRUG, PER 60-DAYS		\$24.000
Q4074	ILOPORST, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM	UP TO 20 MCG	\$148.334
NDC number	BUSULFAN, ORAL	2 MG	INVOICE*
NDC number	CAPECITABINE, ORAL	50 MG	\$0.064
NDC number	CYCLOPHOSPHAMIDE, ORAL	25 MG	\$0.883
NDC number	CYCLOPHOSPHAMIDE, ORAL	50 MG	\$1.766
NDC number	ETOPOSIDE, ORAL	50 MG	\$76.664
IDC number	FLUDARABINE PHOSPHATE, ORAL	10 MG	INVOICE*
IDC number	MELPHALAN, ORAL	2 MG	\$9.709
IDC number	METHOTREXATE, ORAL	2.5 MG	\$0.224
IDC number	METHOTREXATE, ORAL	5 MG	\$0.448
NDC number	METHOTREXATE, ORAL	7.5 MG	\$0.672
NDC number	METHOTREXATE, ORAL	10 MG	\$0.896
NDC number	METHOTREXATE, ORAL	15 MG	\$1.344
NDC number	TEMOZOLOMIDE, ORAL	5 MG	\$0.265

^{*} Invoice indicates an invoice for drug should be submitted when filing claim

^{**} Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier.

DME MAC JURISDICTION C Drug Fees, Pharmacy Dispensing Fees, and Pharmacy Supply Fees

HCPCS Code / NDC Number	Description	Dosage	Fee
NDC number	TEMOZOLOMIDE, ORAL	20 MG	\$1.060
NDC number	TEMOZOLOMIDE, ORAL	100 MG	\$5.300
NDC number	TEMOZOLOMIDE, ORAL	250 MG	\$13.250
NDC number	TOPOTECAN, ORAL	0.25 MG	\$124.860

^{*} Invoice indicates an invoice for drug should be submitted when filing claim

^{**} Effective January 1, 2017, the HCPCS code with the JB modifier no longer has a different fee than the HCPCS code without the JB modifier.